New York Life Investment Management LLC Has $5.78 Million Position in Axon Enterprise, Inc. (NASDAQ:AXON)

New York Life Investment Management LLC increased its stake in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 1.2% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,721 shares of the biotechnology company’s stock after buying an additional 115 shares during the quarter. New York Life Investment Management LLC’s holdings in Axon Enterprise were worth $5,777,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in AXON. Groupama Asset Managment acquired a new stake in Axon Enterprise during the third quarter worth approximately $200,000. Massachusetts Financial Services Co. MA bought a new stake in Axon Enterprise during the third quarter worth $120,553,000. Westfield Capital Management Co. LP lifted its stake in Axon Enterprise by 12.2% during the third quarter. Westfield Capital Management Co. LP now owns 1,175,328 shares of the biotechnology company’s stock worth $469,661,000 after purchasing an additional 127,769 shares during the last quarter. Assenagon Asset Management S.A. lifted its stake in Axon Enterprise by 328.7% during the fourth quarter. Assenagon Asset Management S.A. now owns 145,299 shares of the biotechnology company’s stock worth $86,354,000 after purchasing an additional 111,405 shares during the last quarter. Finally, Champlain Investment Partners LLC lifted its stake in Axon Enterprise by 13.9% during the third quarter. Champlain Investment Partners LLC now owns 682,420 shares of the biotechnology company’s stock worth $272,695,000 after purchasing an additional 83,265 shares during the last quarter. Institutional investors and hedge funds own 79.08% of the company’s stock.

Axon Enterprise Stock Up 0.6 %

Shares of NASDAQ:AXON opened at $528.45 on Friday. The firm has a market cap of $40.30 billion, a P/E ratio of 136.55, a P/E/G ratio of 5.17 and a beta of 1.05. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32. Axon Enterprise, Inc. has a 12-month low of $273.52 and a 12-month high of $715.99. The business has a fifty day simple moving average of $609.55 and a 200 day simple moving average of $523.20.

Insider Buying and Selling

In other Axon Enterprise news, insider Jeffrey C. Kunins sold 2,304 shares of the stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $654.79, for a total transaction of $1,508,636.16. Following the completion of the sale, the insider now directly owns 128,542 shares in the company, valued at approximately $84,168,016.18. This trade represents a 1.76 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the sale, the director now owns 6,929 shares of the company’s stock, valued at approximately $4,185,601.03. The trade was a 6.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 8,711 shares of company stock valued at $5,631,561 in the last three months. Insiders own 6.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AXON. Robert W. Baird upped their target price on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. JMP Securities restated an “outperform” rating on shares of Axon Enterprise in a research note on Tuesday, February 4th. Craig Hallum cut Axon Enterprise from a “buy” rating to a “hold” rating and set a $625.00 target price for the company. in a research note on Thursday, February 20th. Morgan Stanley upgraded Axon Enterprise from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $500.00 to $700.00 in a research note on Tuesday, December 3rd. Finally, Northcoast Research cut Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $587.38.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.